Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 526,423	$ 339,154
Accounts receivable	0	2,045
Prepaid expenses and other current assets	11,406	9,022
Research and development incentives receivable	24,039	19,162
Total current assets	561,868	369,383
Property and equipment, net	14,515	19,110
Operating lease right-of-use assets	13,169	13,658
Other assets	5,792	8,458
Total assets	595,344	410,609
Current liabilities:
Accounts payable	13,050	6,472
Accrued expenses and other current liabilities	31,509	26,452
Deferred revenue, current portion	24,978	20,418
Total current liabilities	69,537	53,342
Long-term debt, net of discount	30,698	30,315
Operating lease liabilities, net of current portion	9,382	10,885
Deferred revenue, net of current portion	110,216	41,455
Other longterm liabilities	4,579	3,829
Total liabilities	224,412	139,826
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 59,612,613 and 57,820,181 shares authorized at December 31, 2023 and December 31, 2022, respectively; 42,431,766 and 29,873,893 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	550	387
Additional paid-in capital	883,446	601,105
Accumulated other comprehensive (loss) income	(1,304)	387
Accumulated deficit	(511,760)	(331,096)
Total shareholders' equity	370,932	270,783
Total liabilities and shareholders' equity	$ 595,344	$ 410,609